Literature DB >> 3995322

Alteration of nicotinic cholinergic agonist binding sites in hippocampus after fimbria transection.

A L Morrow, R Loy, I Creese.   

Abstract

Nicotinic cholinergic agonist binding sites were studied in rat hippocampus by the binding of [3H]acetylcholine in the presence of 1.5 microM atropine sulfate. Following transection of the fimbria/fornix there was a 49% increase in the binding of [3H]acetylcholine reflecting an increase in the affinity of the receptor binding site from Kd = 18.82 +/- 3.6 nM in control animals to Kd = 9.06 +/- 1.2 nM in experimental tissue. Chronic administration of the agonist nicotine (4 mg/kg/day) by osmotic minipumps produced an increase in the binding of 10 nM [3H]acetylcholine after 14 days (49% increase over control) and after 28 days (141% increase over controls). These data are consistent with the suggestion that [3H]acetylcholine labels a nicotinic cholinergic receptor in rat brain. Further they support the notion that some of the termination sites of the septal-cholinergic projection to the hippocampus are nicotinic.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995322     DOI: 10.1016/0006-8993(85)90223-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  The effect of chronic nicotine treatment on nicotine-induced seizures.

Authors:  L L Miner; A C Collins
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Regulation of nicotinic receptors in rat brain following quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine.

Authors:  H el-Bizri; P B Clarke
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

3.  Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases.

Authors:  E K Perry; R H Perry; C J Smith; D J Dick; J M Candy; J A Edwardson; A Fairbairn; G Blessed
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.